文献速递糖尿病

GRADE队列:早期2型糖尿病不同降糖治疗的心电图异常与心血管自主神经病变差异

Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort.
PubMed 文献 · Diabetes Care · 2025-01-01

在GRADE队列中,对4769例病程<10年的2型糖尿病患者分析发现,基线时57.1%存在心电图异常、52.8%存在心电图衍生心血管自主神经病变(CAN)。各治疗组新发心电图异常和CAN的总体发生率相似,但第4年利拉鲁肽组主要心电图异常少于非利拉鲁肽组(9% vs. 13%,P=0.03)。

要点

  • 早期2型糖尿病患者中心电图异常和CAN患病率高,与心血管风险因素相关。
  • 利拉鲁肽组第4年主要心电图异常发生率低于非利拉鲁肽组(9% vs. 13%)。
  • CAN发生率在利拉鲁肽与非利拉鲁肽组间无显著差异(P=0.42)。

核心结论

  • 早期2型糖尿病患者心电图异常和CAN常见,利拉鲁肽可能减少主要心电图异常的发生。

研究设计与样本

  • GRADE队列随机对照研究,纳入4769例单用二甲双胍的2型糖尿病患者,随机加用甘精胰岛素、格列美脲、利拉鲁肽或西格列汀。

主要发现

  • 基线时57.1%存在心电图异常,52.8%存在心电图衍生CAN。
  • 第4年利拉鲁肽组主要心电图异常发生率9%,非利拉鲁肽组13%(P=0.03)。
  • CAN发生率在利拉鲁肽与非利拉鲁肽组间无差异(P=0.42)。
  • 第2年利拉鲁肽组正常R-R间期标准差(SDNN)高于非利拉鲁肽组(P=0.02)。

临床怎么用

  • 对早期2型糖尿病患者应关注心电图异常和CAN的筛查,尤其合并心血管风险因素者。
  • 利拉鲁肽治疗可能有助于减少主要心电图异常的发生。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the prevalence and incidence of electrocardiogram (ECG) abnormalities and ECG-derived cardiovascular autonomic neuropathy (CAN) in the GRADE cohort of adults with type 2 diabetes (T2D) <10 years. RESEARCH DESIGN AND METHODS: Individuals with T2D taking metformin alone were randomly assigned to add insulin glargine, glimepiride, liraglutide, or sitagliptin. Resting ECGs were completed at the baseline, 2-year, and 4-year study visits and analyzed for minor and major abnormalities and CAN assessed with heart rate variability (HRV) in 4,769 participants. Incidence of new major, minor, and any ECG abnormalities and CAN by treatment group was analyzed using logistic repeated-measures models at years 2 and 4 adjusted for baseline risk factors. RESULTS: At baseline, participants were a mean age of 57.2 ± 10.0 years, 36.3% were women, mean diabetes duration was 4.3 ± 2.8 years, and mean HbA1c was 7.5 ± 0.5%. Participants with ECG abnormalities at baseline (57.1%) and ECG-derived CAN (52.8%) were older and had more severe cardiovascular risk factors. The incidence of minor and major ECG abnormalities was similar among all treatment groups. However, at year 4, major ECG abnormalities were fewer in the liraglutide versus nonliraglutide groups (9% vs. 13%; P = 0.03). The incidence of CAN did not differ between the liraglutide and nonliraglutide groups across visits (P = 0.42); however, one measure of HRV (SD of normal-to-normal R-R intervals) was higher at year 2 in the liraglutide versus nonliraglutide groups (P = 0.02). CONCLUSIONS: ECG abnormalities, including those reflecting CAN, are common in individuals with T2D <10 years and more so in those with certain cardiovascular risk factors. The development of major ECG abnormalities may be lower with liraglutide.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Pop-Busui R, Rosin SP, Butera NM, et al. Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort. Diabetes Care. 2025. PMID: 40986645. doi:10.2337/dc25-1087

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。